How has ECOR's revenue mix changed recently?

ElectroCore's (ECOR) revenue mix has shifted significantly, reflecting both opportunities and challenges in their business segments:

1. **Growth in Specific Segments**:
- The company's core revenue, excluding TAC-STIM, grew by 29% year-over-year to $6.6 million.
- The Veterans Affairs (VA) business grew by 22% to $4.7 million.
- Truvaga wellness products experienced exceptional growth, increasing by 187% to $1.1 million.
2. **Declines in Other Segments**:
- The U.S. Commercial prescription business declined by 33%.
- The TAC-STIM product line saw a significant drop of 70%.
3. **Overall Revenue Increase**:
- ElectroCore reported a total revenue of $6.7 million for Q1 2025, marking a 23% increase year-over-year.
4. **Impact of Strategic Acquisitions**:
- The acquisition of NeuroMetrix contributed approximately $170,000 in unaudited Quell net sales for the quarter.
5. **Market Performance and Challenges**:
- Despite revenue growth, the company posted a net loss of $3.9 million, primarily due to increased operating expenses.
- The stock price fell by 2.3% during regular trading and 10.72% in aftermarket trading, reflecting investor concerns over the net loss and reduced cash reserves.
6. **Future Outlook**:
- ElectroCore provided full-year 2025 guidance of approximately $30.0 million in total revenue.
- The company is focusing on expanding its product offerings and partnerships to sustain growth.

In conclusion, ElectroCore has shown strong growth in specific segments such as the VA market and Truvaga sales, but faced challenges in others, leading to a mixed revenue performance. The company's strategic acquisitions and future guidance indicate a focus on expansion and potential recovery.